

Patent  
Attorney's Docket No. 001560-336

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

NORIO INOMATA et al.

Application No.: 09/171,928

Filed: OCTOBER 5, 1998

For: PHARMACEUTICAL COMPOSITION  
FOR TREATMENT OF HEART  
DISEASE BASED ON CARDIAC  
HYPERTROPHY

) ATTENTION:  
) APPLICATIONS BRANCH

) Group Art Unit: 1614

) Examiner:

RECEIVED  
OCT 07 1999  
TECH CENTER 1600/2900

**REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a copy of the Official Filing Receipt marked in red to show correction that is needed. The correction is as follows.

Title of the Invention is: "PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEART DISEASE BASED ON CARDIAC HYPERTROPHY"

Issuance of a corrected Official Filing Receipt is respectfully requested.

☒ This Request for Corrected Official Filing Receipt is being filed to correct a Patent Office error. No fee is required.


☐ The \$25.00 fee required under 37 C.F.R. § 1.19(h) to correct an Official Filing Receipt due to applicant error: ☐ is enclosed; ☐ is authorized to be charged to Deposit Account No. 02-4800 and this paper is submitted in triplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

**BEST AVAILABLE COPY**

By:

  
Dawn M. Gardner

Registration No. 44,118

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/171,928	10/05/98	1614	\$930.00	001560-336	3	5	1

RONALD L GRUDZIECKI  
BURNS DOANE SWECKER & MATHIS  
PO BOX 1404  
ALEXANDRIA VA 22313-1404

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice," the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) NORIO INOMATA, OSAKA, JAPAN; AKIRA YAMAKI, OSAKA, JAPAN;  
MAYUMI FURUYA, OSAKA, JAPAN; TOSHINORI HIDAKA, OSAKA,  
JAPAN.

CONTINUING DATA AS CLAIMED BY APPLICANT-  
THIS APPLN IS A 371 OF PCT/JP98/00483 02/05/98

FOREIGN APPLICATIONS- JAPAN 9-22594 02/05/97

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 08/12/99  
TITLE

MEDICINAL COMPOSITIONS FOR TREATING CARDIAC DISEASES CAUSED BY  
CARDIAC HYPERTROPHY

PRELIMINARY CLASS: 514

TITLE SHOULD READ: PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEART DISEASE  
BASED ON CARDIAC HYPERTROPHY

RECEIVED  
F/16  
AUG 16 1999  
001560-336  
Aoki  
KLG/DMM

DATA ENTRY BY: LA SANE, LATICIA TEAM: 11 DATE: 08/12/99

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE ---- The Following Information about the Filing Receipt:**

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement," "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each (letters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Customer Address may have been modified to conform to U.S. Postal rules.

Please direct correction, including a copy of your Filing Receipt, to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20221